SMMT — Summit Therapeutics Balance Sheet
0.000.00%
- $15.59bn
- $15.29bn
Annual balance sheet for Summit Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 66.4 | 71.8 | 349 | 186 | 412 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 10.2 | 17.2 | 6.12 | 0.848 | 0.557 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 87.7 | 97.3 | 657 | 190 | 424 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.28 | 3.48 | 5.08 | 6.06 | 7.4 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 102 | 113 | 664 | 203 | 436 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 19.9 | 25.6 | 38.8 | 20.4 | 41.7 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 23 | 30.1 | 538 | 125 | 46.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 79.5 | 83.3 | 127 | 77.7 | 389 |
| Total Liabilities & Shareholders' Equity | 102 | 113 | 664 | 203 | 436 |
| Total Common Shares Outstanding |